Abstract
KEYWORDS: Biosimilar orphansbiosimilarrare diseaseorphan biologicsbiosimilar monoclonal antibodybiosimilar developmentlogistics and limitations of orphan biosimilarsclinical limitations of orphanspricing of orphansreimbursement orphans
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have